Table 2.
Adverse events reported by ≥30% of patients overall, by maximum reported grade
| |
Evaluable patients, n (%) |
||||
|---|---|---|---|---|---|
| |
Cohort 1 |
Cohort 2 |
Overall |
||
| |
(n = 9) |
(n = 10) |
(n = 19) |
||
| Grade 1/2 | Grade ≥3 | Grade 1/2 | Grade ≥3 | ||
| Diarrhea |
6 (67) |
0 |
6 (60) |
0 |
12 (63) |
| Nausea |
5 (56) |
0 |
6 (60) |
0 |
11 (58) |
| Neutropenia |
3 (33) |
4 (44)a |
2 (20) |
2 (20)b |
11 (58) |
| Alopecia |
6 (67) |
0 |
4 (40) |
0 |
10 (53) |
| Fatigue |
6 (67) |
0 |
3 (30) |
1 (10) |
10 (53) |
| Anemia |
3 (33) |
2 (22) |
1 (10) |
0 |
6 (32) |
| Constipation |
4 (44) |
0 |
2 (20) |
0 |
6 (32) |
| Peripheral neuropathy |
3 (33) |
0 |
3 (30) |
0 |
6 (32) |
| Rash |
1 (11) |
0 |
5 (50) |
0 |
6 (32) |
| Vomiting | 3 (33) | 0 | 3 (30) | 0 | 6 (32) |
aIncludes one grade 4 event.
bIncludes one case of febrile neutropenia.